{"entity":{"id":"nct06005974","kind":"trial","name":"A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation","aka":[],"tldr":"A phase 2 trial of REC-4881 run by Recursion Pharmaceuticals Inc., terminated.","summary":"A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation is a phase 2 interventional study registered as NCT06005974 by Recursion Pharmaceuticals Inc., with 18 participants enrolled, started 2024-01-15. Conditions recorded: AXIN1 Gene Mutation, APC Gene Mutation and Solid Tumor. Interventions recorded: REC-4881.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06005974","url":"https://clinicaltrials.gov/study/NCT06005974"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rec-4881"],"companies":["recursion"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06005974","phase":"2","setting":"A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation","sponsor":"Recursion Pharmaceuticals Inc.","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06005974/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rec-4881","kind":"drug","name":"REC-4881","route":"/drugs/rec-4881/"}],"company":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/"}]}}